Sorry but this is immunotherapy that has to do with blood, the vaccine goes into the bloodstream to activate the immune system, does not work by using the vaccine near the genitals into the flesh
- Forums
- ASX - By Stock
- AVR
- Ann: Admedus Releases Results of HSV-2 Phase IIa Study
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-347
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$9.61 |
Change
-0.300(3.03%) |
Mkt cap ! $202.9M |
Open | High | Low | Value | Volume |
$9.50 | $9.61 | $9.31 | $106.1K | 11.17K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 680 | $9.41 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.51 | 299 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 732 | 9.410 |
1 | 99 | 9.310 |
1 | 2000 | 9.300 |
2 | 1044 | 9.250 |
2 | 412 | 9.200 |
Price($) | Vol. | No. |
---|---|---|
9.670 | 923 | 6 |
9.680 | 161 | 1 |
9.690 | 180 | 1 |
9.700 | 180 | 1 |
9.910 | 13 | 1 |
Last trade - 13.16pm 13/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online